PMN : TSX  |  ARFXF : OTCQB

Developing Treatments for Neurodegenerative Diseases 

ProMIS is using their unique technology to develop highly selective antibody treatments for neurodegenerative diseases including Alzheimer's, ALS and Parkinson's disease.

ProMIS will continue to demonstrate potential for their lead antibody candidate as best-in-class Alzheimer's therapy and plans to initiate clinical trials in 2019.

Their lead antibody candidate for Alzheimer's, selectively targets what the expert community now identifies as the root cause of Alzheimer’s disease.

Investment Highlights

Massive Unmet Medical Need

Management Team

Broad Product Portfolio in Neurodegenerative Diseases

No therapies available today to stop the progression of Alzheimer’s disease (AD). Total U.S. AD costs are expected to increase from $277 billion in 2018, to more than $1.1 trillion in 2050.

Knowledgeable, complementary management team with outstanding scientific and business advisory boards.

Discovery platform allows identification of therapeutic targets on toxic oligomers responsible for diseases, including Alzheimer’s disease, ALS, Parkinson’s disease and other dementias.

New Hope: Treating Alzheimer's

Copyright © 2018. All rights reserved.

Presented By: